The Readout

The Readout Meghana Keshavan

STAT Plus: A potential rival for Wegovy and Zepbound enters the fray

The Readout Elaine Chen

STAT Plus: Merck lays off workers amid rough pharma job market

The Readout Elaine Chen

STAT Plus: Contradictory coverage decisions in North Carolina

The Readout Meghana Keshavan

STAT Plus: Four health care and biotech updates to stay on top of this week

The Readout Meghana Keshavan

STAT Plus: Novo, Lilly shares sink due to concerns over competition

The Readout Elaine Chen

STAT Plus: The biotech news stories you need to know today

The Readout Elaine Chen

STAT Plus: It’s happy hour (for now) for Alnylam

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

The Readout Elaine Chen

STAT Plus: Intellia says its CRISPR-based therapy can be redosed

The Readout Elaine Chen

STAT Plus: One firm, two conflicting takes on Alnylam’s HELIOS-B 

The Readout Meghana Keshavan

STAT Plus: The findings from Alnylam’s highly anticipated readout  

The Readout Meghana Keshavan

STAT Plus: Can JAK inhibitors bolster checkpoint inhibitors? 

The Readout Elaine Chen

STAT Plus: Lilly takes more actions against unapproved versions of Mounjaro

The Readout Adam Feuerstein

STAT Plus: A biotech’s binary bet ends badly

The Readout Meghana Keshavan

STAT Plus: FDA offers new guidelines for Covid-19 vaccine

The Readout Elaine Chen

STAT Plus: J.P. Morgan has officially jumped into early stage biotech investing

The Readout Meghana Keshavan

With Avidity and Pfizer, gene therapy enters a phase

The Readout Elaine Chen

STAT Plus: What do Parkinson’s and obesity have in common?

The Readout Elaine Chen

Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know

The Readout Meghana Keshavan

The biotech news you missed from the weekend

The Readout Meghana Keshavan

STAT Plus: Vanda Pharmaceuticals has another suitor